Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review

Albutrepenonacog-alfa (Idelvion(®), CSL Behring) is a recombinant fusion protein in which the recombinant FIX (rFIX) links a recombinant human albumin, extending the half-life of rFIX even beyond 100 hours. In 2016, this drug was approved worldwide for the treatment of pediatric and adult persons wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasca, Samantha, Zanon, Ezio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484766/
https://www.ncbi.nlm.nih.gov/pubmed/36132333
http://dx.doi.org/10.2147/DDDT.S236788
_version_ 1784791943327252480
author Pasca, Samantha
Zanon, Ezio
author_facet Pasca, Samantha
Zanon, Ezio
author_sort Pasca, Samantha
collection PubMed
description Albutrepenonacog-alfa (Idelvion(®), CSL Behring) is a recombinant fusion protein in which the recombinant FIX (rFIX) links a recombinant human albumin, extending the half-life of rFIX even beyond 100 hours. In 2016, this drug was approved worldwide for the treatment of pediatric and adult persons with hemophilia B (PWH-B). Its efficacy and safety were described in the PROLONG-9FP program and subsequently confirmed in the real-world practice, even if to date there are not many manuscripts that extensively and completely deal with the use of albutrepenonacog-alfa in daily practice, also evaluating its impact on the quality of life of patients treated with this drug; this review therefore aims to analyze all the publications currently available regarding the real-world use of this extended half-life concentrate, also noting which topics need further study and research.
format Online
Article
Text
id pubmed-9484766
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94847662022-09-20 Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review Pasca, Samantha Zanon, Ezio Drug Des Devel Ther Review Albutrepenonacog-alfa (Idelvion(®), CSL Behring) is a recombinant fusion protein in which the recombinant FIX (rFIX) links a recombinant human albumin, extending the half-life of rFIX even beyond 100 hours. In 2016, this drug was approved worldwide for the treatment of pediatric and adult persons with hemophilia B (PWH-B). Its efficacy and safety were described in the PROLONG-9FP program and subsequently confirmed in the real-world practice, even if to date there are not many manuscripts that extensively and completely deal with the use of albutrepenonacog-alfa in daily practice, also evaluating its impact on the quality of life of patients treated with this drug; this review therefore aims to analyze all the publications currently available regarding the real-world use of this extended half-life concentrate, also noting which topics need further study and research. Dove 2022-09-15 /pmc/articles/PMC9484766/ /pubmed/36132333 http://dx.doi.org/10.2147/DDDT.S236788 Text en © 2022 Pasca and Zanon. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Pasca, Samantha
Zanon, Ezio
Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
title Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
title_full Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
title_fullStr Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
title_full_unstemmed Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
title_short Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
title_sort albumin-fusion recombinant fix in the management of people with hemophilia b: an evidence-based review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484766/
https://www.ncbi.nlm.nih.gov/pubmed/36132333
http://dx.doi.org/10.2147/DDDT.S236788
work_keys_str_mv AT pascasamantha albuminfusionrecombinantfixinthemanagementofpeoplewithhemophiliabanevidencebasedreview
AT zanonezio albuminfusionrecombinantfixinthemanagementofpeoplewithhemophiliabanevidencebasedreview

Ejemplares similares